Cargando…

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

BACKGROUND: Most patients with KIT-mutant gastrointestinal stromal tumours (GISTs) benefit from imatinib, but treatment resistance results from outgrowth of heterogeneous subclones with KIT secondary mutations. Once resistance emerges, targeting KIT with tyrosine kinase inhibitors (TKIs) sunitinib a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Serrano, César, Mariño-Enríquez, Adrián, Tao, Derrick L., Ketzer, Julia, Eilers, Grant, Zhu, Meijun, Yu, Channing, Mannan, Aristotle M., Rubin, Brian P., Demetri, George D., Raut, Chandrajit P., Presnell, Ajia, McKinley, Arin, Heinrich, Michael C., Czaplinski, Jeffrey T., Sicinska, Ewa, Bauer, Sebastian, George, Suzanne, Fletcher, Jonathan A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462042/ https://www.ncbi.nlm.nih.gov/pubmed/30792533 http://dx.doi.org/10.1038/s41416-019-0389-6

Ejemplares similares

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
por: Nakayama, Robert, et al.
Publicado: (2016)

The role of c-kit and imatinib mesylate in uveal melanoma
por: Pereira, Patricia Rusa, et al.
Publicado: (2005)

Dystrophin Is a Tumor Suppressor in Human Cancers with Myogenic Programs
por: Wang, Yuexiang, et al.
Publicado: (2014)

Targeted therapy and personalized medicine in gastrointestinal stromal tumors: drug resistance, mechanisms, and treatment strategies
por: Li, George Z, et al.
Publicado: (2019)

LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma
por: Klug, Lillian R., et al.
Publicado: (2018)

Inhibition of c-Kit Is Not Required for Reversal of Hyperglycemia by Imatinib in NOD Mice
por: Lau, Janet, et al.
Publicado: (2014)

TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
por: Saito, Yurina, et al.
Publicado: (2019)

Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2019)

MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation
por: Schaefer, Inga-Marie, et al.
Publicado: (2017)

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
por: Handolias, D, et al.
Publicado: (2010)

Sustained response to imatinib in patient with extraskeletal myxoid chondrosarcoma and novel KIT mutation
por: Jennings, Brooke, et al.
Publicado: (2021)

Response to Imatinib in a Patient with Double-mutant KIT Metastatic Penile Melanoma
por: BEAUDOUX, Olivia, et al.
Publicado: (2021)

Budgetary Impact of Treatment with Adjuvant Imatinib for 1 Year Following Surgical Resection of Kit-Positive Localized Gastrointestinal Stromal Tumors
por: Rubin, Jamie L., et al.
Publicado: (2010)

Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs
por: Flavahan, William A, et al.
Publicado: (2019)

Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I
por: Orlova, Kristina V., et al.
Publicado: (2019)

Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib
por: Zhu, Guangrong, et al.
Publicado: (2020)

KIT and PDGFRA Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib
por: Joensuu, Heikki
Publicado: (2023)

Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948)
por: Raut, Chandrajit P., et al.
Publicado: (2012)

Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs)
por: Heinrich, Michael C., et al.
Publicado: (2019)

Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors
por: Edris, Badreddin, et al.
Publicado: (2013)

Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation
por: IRIE, Mitsuhiro, et al.
Publicado: (2015)

Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: A case report
por: Abdou, Yara, et al.
Publicado: (2019)

Impact of the KIT/PDGFRA genotype on prognosis in imatinib‐naïve Japanese patients with gastrointestinal stromal tumor
por: Cho, Haruhiko, et al.
Publicado: (2021)

Imatinib Responsiveness in Canine Mast Cell Tumors Carrying Novel Mutations of c-KIT Exon 11
por: NAKANO, Yuko, et al.
Publicado: (2013)

Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor
por: Yim, Eunjung, et al.
Publicado: (2018)

Identification of Thiazolo[5,4-b]pyridine Derivatives as c-KIT Inhibitors for Overcoming Imatinib Resistance
por: Nam, Yunju, et al.
Publicado: (2022)

Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation
por: Wakai, T, et al.
Publicado: (2004)

Imatinib response of gastrointestinal stromal tumor patients with germline mutation on KIT exon 13: A family report
por: Engin, Gulgun, et al.
Publicado: (2017)

Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate
por: Rausch, Jessica L., et al.
Publicado: (2016)

KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
por: Joensuu, Heikki, et al.
Publicado: (2023)

Virtual Interviews for the Complex General Surgical Oncology Fellowship: The Dana-Farber/Partners Experience
por: Molina, George, et al.
Publicado: (2020)

Periorbital edema secondary to imatinib mesylate
por: McClelland, Collin M, et al.
Publicado: (2010)

Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors
por: Benjamin, Robert S., et al.
Publicado: (2010)

A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis
por: Kurtz, Jean-Emmanuel, et al.
Publicado: (2010)

Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma
por: Zukotynski, Katherine, et al.
Publicado: (2014)

Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib‐induced KIT mutations in gastrointestinal stromal tumours
por: Liu, Juan, et al.
Publicado: (2022)

Management of Recurrent Retroperitoneal Sarcoma
por: Jolissaint, Joshua S., et al.
Publicado: (2023)

Parental considerations during complementary feeding in higher income countries: a systematic review of qualitative evidence
por: Spyreli, Eleni, et al.
Publicado: (2021)

Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1
por: Hemming, Matthew L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q4jsp2haav03ou214jq3im5u56